Patient: WILLIAM

HEMSWORTH
DOB: May 13, 1993
Sex: M
MRN: 1232435877

Melanie Jones
11 a Eagle Brow
Lymm, Cheshire WA13 0LP
Great Britain and Northern Ireland

Order Number: I2070220

Completed: February 24, 2015 01:00
Received: February 10, 2015 16:43
Collected: February 04, 2015 14:20
Route Number: IW87017

GI Effects Comprehensive Profile - Stool

Interpretation At-a-Glance
INFECTION

INFLAMMATION

INSUFFICIENCY
Fecal Fats (Total)

DIVERSITY ASSOCIATION

IMBALANCE
Beneficial Bacteria

RELATIVE ABUNDANCE

Verrucomicrobia Phylum
Fusobacteria Phylum
Euryarchaeota Phylum
Proteobacteria Phylum
Actinobacteria Phylum

PATIENT
RESULTS

HEALTHY
COHORT

Genova Diagnostics Robert M. David, PhD, Lab Director CLIA Lic. #11D0255349 Medicare Lic. #34-8475 Georgia Lab Lic. Code #067-007
New York Clinical Lab PFI #4578 Florida Clinical Lab Lic. #800008124

Firmicutes Phylum
Bacteroidetes Phylum

2200A

Patient: WILLIAM HEMSWORTH

GI Effects Comprehensive Profile - Stool

Methodology: GC/MS, Automated Chemistry, EIA

Page 2

ID: I2070220

Results

QUINTILE DISTRIBUTION

1st

2nd

3rd

4th

5th

Reference Range

Digestion and Absorption

Pancreatic Elastase 1

398

Products of Protein Breakdown (Total*)

(Valerate, Isobutyrate, Isovalerate)

4.3

100

200

>200 mcg/g
1.8-9.9 micromol/g

Fecal Fat (Total*)

57.1 H

3.2-38.6 mg/g

Triglycerides

13.1 H

0.3-2.8 mg/g

Long-Chain Fatty Acids

30.1 H

1.2-29.1 mg/g

Cholesterol
Phospholipids

1.2

0.4-4.8 mg/g

12.7 H

0.2-6.9 mg/g

Inflammation and Immunology

Calprotectin

<17

Eosinophil Protein X (EPX)

0.6

Fecal secretory IgA**

283

50

120

<=50 mcg/g
7

<=7.0 mcg/g
<=885 mcg/g

Gastrointestinal Microbiome
Metabolic
Short-Chain Fatty Acids (SCFA) (Total*)
(Acetate, n-Butyrate, Propionate)

57.6

>=23.3 micromol/g

n-Butyrate Concentration

13.6

>=3.6 micromol/g

n-Butyrate %

23.6

11.8-33.3 %

Acetate %

56.8

48.1-69.2 %

Propionate %

19.6

<=29.3 %

Beta-glucuronidase

3,653

368-6,266 U/g

*Total value is equal to the sum of all measurable parts.

These results are not represented by quintile values.
** Indicates testing performed by Genova Diagnostics, Inc. 63 Zillicoa St., Asheville, NC 28801-0174
A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director CLIA Lic. #34D0655571 Medicare Lic. #34-8475

Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless otherwise noted with , the assays have not been cleared or approved by
the U.S. Food and Drug Administration.
Genova Diagnostics Robert M. David, PhD, Lab Director CLIA Lic. #11D0255349 Medicare Lic. #34-8475 Georgia Lab Lic. Code #067-007
New York Clinical Lab PFI #4578 Florida Clinical Lab Lic. #800008124

2200A

Patient: WILLIAM HEMSWORTH

Page 3

ID: I2070220

Methodology: DNA by PCR

Gastrointestinal Microbiome
Commensal Bacteria (PCR)

Result

CFU/g stool

1st

QUINTILE DISTRIBUTION

2nd

3rd

4th

5th

Reference Range
CFU/g stool

Bacteroidetes Phylum

1.1E9

3.4E6 -1.5E9

8.8E9 H

<=2.2E9

Barnesiella spp.

2.7E8 H

<=1.6E8

Odoribacter spp.

1.3E8 H

<=8.0E7

Prevotella spp.

3.3E6

1.4E5 -1.6E7

Anaerotruncus colihominis

3.9E6

<=3.2E7

Butyrivibrio crossotus

6.9E4

5.5E3 -5.9E5

Clostridium spp.

1.3E9

1.7E8 -1.5E10

Coprococcus eutactus

3.7E5

<=1.2E8

Bacteroides-Prevotella group
Bacteroides vulgatus

Firmicutes Phylum

Faecalibacterium prausnitzii

1.0E10 H

5.8E7 -4.7E9

Lactobacillus spp.

9.1E7

8.3E6 -5.2E9

Pseudoflavonifractor spp.

4.9E7

4.2E5 -1.3E8

Roseburia spp.

8.0E9

1.3E8 -1.2E10

Ruminococcus spp.

1.2E8

9.5E7 -1.6E9

Veillonella spp.

4.8E7

1.2E5 -5.5E7

3.0E8

<=6.4E9

3.5E7

<=7.2E8

2.1E8

1.4E7 -1.9E9

Desulfovibrio piger

7.4E7 H

<=1.8E7

Escherichia coli

9.9E5

9.0E4 -4.6E7

Oxalobacter formigenes

4.4E6

<=1.5E7

5.6E6

<=8.6E7

4.2E4

<=2.4E5

4.3E5 L

>=1.2E6

Actinobacteria Phylum

Bifidobacterium spp.
Bifidobacterium longum
Collinsella aerofaciens
Proteobacteria Phylum

Euryarchaeota Phylum

Methanobrevibacter smithii
Fusobacteria Phylum

Fusobacterium spp.
Verrucomicrobia Phylum

Akkermansia muciniphila

Firmicutes/Bacteroidetes Ratio

Firmicutes/Bacteroidetes (F/B Ratio)

14

12-620

The gray-shaded portion of a quintile reporting bar represents the proportion of the reference population with results below detection limit.
Commensal results and reference range values are displayed in a computer version of scientific notation, where the capital letter E indicates the exponent
value (e.g., 7.3E6 equates to 7.3 x 10 or 7,300,000).
The Firmicutes/Bacteroidetes ratio (F/B Ratio) is estimated by utilizing the lowest and highest values of the reference range for individual organisms when patient results are
reported as <DL or >UL.
Genova Diagnostics Robert M. David, PhD, Lab Director CLIA Lic. #11D0255349 Medicare Lic. #34-8475 Georgia Lab Lic. Code #067-007
New York Clinical Lab PFI #4578 Florida Clinical Lab Lic. #800008124

Patient: WILLIAM HEMSWORTH

Page 4

ID: I2070220

Methodology: Culture/MALDI-TOF MS, Automated and Manual Biochemical Methods, Vitek 2 System Microbial identification and Antibiotic susceptibility

Gastrointestinal Microbiome
1+

Bacteriology (Culture)
Lactobacillus spp.

3+ NP

Escherichia coli

3+ NP

Bifidobacterium

3+ NP

2+

3+

4+

Additional Bacteria
alpha haemolytic Streptococcus

1+ NP

Staphylococcus aureus

3+ NP

Mycology (Culture)
Rhodotorula species

1+ NP

Additional Bacteria
Human microflora is influenced by environmental factors and the
competitive ecosystem of the organisms in the GI tract.
Pathogenic significance should be based upon clinical symptoms.

Potential Pathogen: Organisms that fall under this category are

considered potential or opportunistic pathogens when present in
heavy growth.

Microbiology Legend
NG

No Growth

NP

NonPathogen

PP

Potential
Pathogen

Non-Pathogen: Organisms that fall under this category are

those that constitute normal, commensal flora, or have not been
recognized as etiological agents of disease.

Pathogen

Pathogen: The organisms that fall under this category have a

well-recognized mechanism of pathogenicity in clinical literature
and are considered significant regardless of the quantity that
appears in the culture.

Genova Diagnostics Robert M. David, PhD, Lab Director CLIA Lic. #11D0255349 Medicare Lic. #34-8475 Georgia Lab Lic. Code #067-007
New York Clinical Lab PFI #4578 Florida Clinical Lab Lic. #800008124

Patient: WILLIAM HEMSWORTH

Page 5

ID: I2070220

Methodology: Direct Microscopic Examination, EIA

Parasitology
Microscopic Exam Results**
Parasitology

No Ova or Parasites seen

Parasite Recovery: Literature suggests

that >90% of enteric parasitic infections
may be detected in a sample from a
single stool collection. Increased
sensitivity results from the collection of
additional specimens on separate days.

Parasitology EIA Tests:

In Range

Cryptosporidium

Negative

Giardia lamblia

Negative

Entamoeba histolytica

Negative

Out of Range

** Indicates testing performed by Genova Diagnostics, Inc. 63 Zillicoa St., Asheville, NC 28801-0174
A. L. Peace-Brewer, PhD, D(ABMLI), Lab Director - CLIA Lic. #34D0655571 - Medicare Lic. #34-8475
Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless otherwise noted with , the assays have not been cleared or approved by
the U.S. Food and Drug Administration.
Genova Diagnostics Robert M. David, PhD, Lab Director CLIA Lic. #11D0255349 Medicare Lic. #34-8475 Georgia Lab Lic. Code #067-007
New York Clinical Lab PFI #4578 Florida Clinical Lab Lic. #800008124

Patient: WILLIAM HEMSWORTH

Page 6

ID: I2070220

Methodology: EIA, Fecal Immunochemical Testing (FIT)

Additional Results
Result

Expected Value

Fecal Occult Blood

Negative

Negative

Consistency

Hard/Constip.

Lab Comments (if applicable)

Lab Comments
plant tannins is not available for yeast botanicals.
02/16/2015 MF
SENSI'S: All yeast, add'l bacteria

Results provided from patient input.

Tests were developed and their performance characteristics determined by Genova Diagnostics. Unless otherwise noted with , the assays have not been cleared or approved by
the U.S. Food and Drug Administration.
Genova Diagnostics Robert M. David, PhD, Lab Director CLIA Lic. #11D0255349 Medicare Lic. #34-8475 Georgia Lab Lic. Code #067-007
New York Clinical Lab PFI #4578 Florida Clinical Lab Lic. #800008124

Patient: WILLIAM HEMSWORTH

Page 7

ID: I2070220

Mycology Sensitivity
Prescriptive Agents
Rhodotorula species

Prescriptive Agents:
S

Fluconazole

Itraconazole

Nystatin
Rhodotorula species

LOW INHIBITION

HIGH INHIBITION

LOW INHIBITION

HIGH INHIBITION

Nystatin

Natural Agents
Rhodotorula species
Berberine
Caprylic Acid
Garlic
Undecylenic Acid

Microbial testing has been performed

in vitro to determine antibiotic
sensitivity and resistance at standard
dosages. Prudent use of
antimicrobials requires knowledge of
appropriate blood or tissue levels of
those agents. Antibiotics that appear
in the "S" (susceptible) column are
more effective at inhibiting the growth
of this organism. Antibiotics that
appear in the "I" (intermediate) column
are partially effective at inhibiting the
growth of this organism. Antibiotics
that appear in the "R" (resistant)
column allow continued growth of the
organism in vitro and are usually less
effective clinically. Inappropriate use
of antibacterials often results in the
emergence of resistance.

Uva-Ursi

Natural Agents:
In this assay, "inhibition" is defined
as the reduction level on organism
growth as a direct result of inhibition
by a natural substance. The level of
inhibition is an indicator of how
effective the natural substance was
at limiting the growth of an organism
in an in vitro environment. High
inhibition indicates a greater ability by
the natural substance to limit growth,
while Low Inhibition a lesser ability to
limit growth. These natural products
should be considered investigational
in nature and not be viewed as
standard clinical treatment
substances.

Genova Diagnostics Robert M. David, PhD, Lab Director CLIA Lic. #11D0255349 Medicare Lic. #34-8475 Georgia Lab Lic. Code #067-007
New York Clinical Lab PFI #4578 Florida Clinical Lab Lic. #800008124